QPI-1007

also known as ADX-038 · ADX-324 · ADX-850 · siRNA

Small interfering RNA (siRNA) targets SPARC

Trials 10 · a red edge is where a trial was stopped

today NCT07596628 · Ph 2 NCT07522099 · Ph 2 NCT07428499 · Ph 3 NCT06990269 · Ph 2 NCT06960213 · Ph 3 NCT06989359 · Ph 2 NCT06205628 · Ph 1 NCT05876312 · Ph 1/2 NCT05691361 · Ph 1/2 NCT01064505 · Ph 1

2010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT06205628	Mar 2024 → Jul 2026 overdue	essential hypertension	ADARx Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 1	NCT01064505	Feb 2010 → Apr 2013	non-arteritic anterior ischemic optic neuropathy, optic atrophy	Quark Pharmaceuticals	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT05876312	Aug 2023 → Mar 2028 expected	paroxysmal nocturnal hemoglobinuria	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT05691361	Dec 2022 → Dec 2027 expected	hereditary angioedema	ADARx Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 24 trials
Phase 2	NCT07596628	Jun 2026 → Dec 2027 expected	keloid formation	Ong Kim Yao	Not yet recruiting	No outcome recorded
Phase 2	NCT07522099	May 2026 → Jul 2028 expected	IgA glomerulonephritis, complement 3 glomerulopathy, membranoproliferative glomerulonephritis	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 2	NCT06990269	Nov 2025 → Feb 2030 expected	age-related macular degeneration	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 2	NCT06989359	Aug 2025 → Dec 2028 expected	IgA glomerulonephritis, complement 3 glomerulopathy, immunoglobulin-mediated membranoproliferative glomerulonephritis	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 32 trials
Phase 3	NCT07428499	Apr 2026 → Jun 2030 expected	hereditary angioedema type 1, hereditary angioedema type 2	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06960213	Aug 2025 → Jun 2027 expected	hereditary angioedema type 1, hereditary angioedema type 2	ADARx Pharmaceuticals, Inc.	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT01965106 Comparator	Dec 2013 → Jun 2015	primary angle-closure glaucoma	Quark Pharmaceuticals	Completed	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT02341560 Comparator	Feb 2016 → Jul 2019	non-arteritic anterior ischemic optic neuropathy	Quark Pharmaceuticals	Terminated	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	QPI-1007	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01064505 ↗ 2 NCT02341560 ↗ NCT01965106 ↗
Known as	ADX-038	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06989359 ↗ 3 NCT05876312 ↗ NCT06990269 ↗ NCT07522099 ↗
Known as	ADX-324	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06960213 ↗ 2 NCT07428499 ↗ NCT05691361 ↗
Known as	ADX-850	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205628 ↗
Known as	siRNA	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07596628 ↗
Modality	Small interfering RNA (siRNA)	“siRNA” NCT01064505 ↗
Route	Intravitreal	“Single Intravitreal Injection” NCT01064505 ↗
Target	SPARC	“These siRNA nanoplexes targeting SPARC mRNA” NCT07596628 ↗